
CareDx, Inc CDNA
$ 16.68
-4.55%
Annual report 2025
added 02-25-2026
CareDx, Inc Accounts Receivables 2011-2026 | CDNA
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables CareDx, Inc
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 42.6 M | 64.6 M | 51.1 M | 66.3 M | 59.8 M | 34.6 M | 24.1 M | 9.76 M | 2.99 M | - | 2.37 M | 2.69 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 66.3 M | 2.37 M | 32.8 M |
Quarterly Accounts Receivables CareDx, Inc
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 47.8 M | 67.4 M | 71.5 M | 64.6 M | 66.6 M | 66.2 M | 60.1 M | 51.1 M | 51.7 M | 51.6 M | 59.3 M | 66.3 M | 70.4 M | - | 65.3 M | 59.8 M | 56.2 M | 48.1 M | 43.4 M | 34.6 M | 34.6 M | 34.6 M | 34.6 M | 24.1 M | 24.1 M | 24.1 M | 24.1 M | 9.76 M | 9.76 M | 9.76 M | 9.76 M | 2.99 M | 2.99 M | 2.99 M | 2.99 M | 2.77 M | 4.57 M | 4.89 M | 2.51 M | 2.37 M | 2.37 M | 2.37 M | 2.37 M | 2.69 M | 2.69 M | 2.69 M | 2.69 M | 2.27 M | 2.27 M | 2.27 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 71.5 M | 2.27 M | 28.5 M |
Accounts Receivables of other stocks in the Diagnostics research industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Agilent Technologies
A
|
1.17 B | $ 110.31 | -2.79 % | $ 33.5 B | ||
|
Waters Corporation
WAT
|
829 M | $ 289.46 | -3.69 % | $ 17.2 B | ||
|
Enzo Biochem
ENZ
|
3.99 M | - | -8.98 % | $ 14.8 K | ||
|
Exact Sciences Corporation
EXAS
|
299 M | - | - | $ 19.8 B | ||
|
Akumin
AKU
|
114 M | - | -17.87 % | $ 25.9 M | ||
|
Sotera Health Company
SHC
|
139 M | $ 13.12 | -3.14 % | $ 3.73 B | ||
|
Heska Corporation
HSKA
|
29.5 M | - | - | $ 1.31 B | ||
|
BioNano Genomics
BNGO
|
5.2 M | $ 1.15 | -0.43 % | $ 6.26 M | ||
|
DermTech
DMTK
|
2.58 M | - | -11.32 % | $ 2.94 M | ||
|
Aspira Women's Health
AWH
|
1.24 M | - | -6.19 % | $ 10.5 M | ||
|
DexCom
DXCM
|
1.22 B | $ 62.39 | -5.61 % | $ 24.3 B | ||
|
Accelerate Diagnostics
AXDX
|
2.42 M | - | -61.36 % | $ 2.46 M | ||
|
Global Cord Blood Corporation
CO
|
416 M | - | - | $ 399 M | ||
|
HTG Molecular Diagnostics
HTGM
|
1.42 M | - | -20.0 % | $ 1.06 M | ||
|
Castle Biosciences
CSTL
|
51.2 M | $ 23.59 | -4.49 % | $ 655 M | ||
|
Charles River Laboratories International
CRL
|
709 M | $ 158.5 | -4.02 % | $ 7.86 B | ||
|
Quest Diagnostics Incorporated
DGX
|
1.41 B | $ 195.05 | -1.56 % | $ 21.7 B | ||
|
Organovo Holdings
ONVO
|
30 K | - | -2.3 % | $ 19.4 M | ||
|
OpGen
OPGN
|
29.3 K | - | -16.95 % | $ 1.54 M | ||
|
Biocept
BIOC
|
2.15 M | - | -13.05 % | $ 7.29 M | ||
|
PerkinElmer
PKI
|
783 M | - | -0.91 % | $ 14.7 B | ||
|
Invitae Corporation
NVTA
|
96.1 M | - | - | $ 21.2 M | ||
|
Interpace Biosciences
IDXG
|
8.54 M | $ 1.68 | -2.89 % | $ 7.37 M | ||
|
Motus GI Holdings
MOTS
|
76 K | - | -34.28 % | $ 263 K | ||
|
QIAGEN N.V.
QGEN
|
381 M | - | - | $ 10.6 B | ||
|
Neogen Corporation
NEOG
|
153 M | $ 8.71 | -4.86 % | $ 1.89 B | ||
|
Chembio Diagnostics
CEMI
|
6.54 M | - | 0.22 % | $ 16.8 M | ||
|
Laboratory Corporation of America Holdings
LH
|
2.1 B | $ 264.08 | -1.6 % | $ 22 B | ||
|
Psychemedics Corporation
PMD
|
3.69 M | - | -1.84 % | $ 15.3 M | ||
|
Precipio
PRPO
|
1.3 M | $ 25.69 | -5.55 % | $ 33.3 M | ||
|
Quotient Limited
QTNT
|
5.32 M | - | -11.32 % | $ 1.1 M | ||
|
Syneos Health
SYNH
|
729 M | - | - | $ 4.46 B | ||
|
Renalytix AI plc
RNLX
|
100 K | - | 5.66 % | $ 22.7 M | ||
|
VolitionRx Limited
VNRX
|
111 K | $ 0.19 | -0.08 % | $ 18.3 M | ||
|
Biodesix
BDSX
|
8.6 M | $ 14.29 | -2.16 % | $ 1.85 B | ||
|
Biomerica
BMRA
|
731 K | $ 1.99 | -5.52 % | $ 4.57 M | ||
|
Burning Rock Biotech Limited
BNR
|
88.2 M | $ 16.61 | -10.22 % | $ 179 M | ||
|
Bioventus
BVS
|
128 M | $ 8.93 | -3.62 % | $ 595 M | ||
|
Co-Diagnostics
CODX
|
304 K | $ 4.4 | 101.83 % | $ 129 M | ||
|
Meridian Bioscience
VIVO
|
47.2 M | - | - | $ 1.49 B |